Docetaxel Plus Ramucirumab May Be Effective for Urothelial Carcinoma

Share this content:
Adding ramucirumab to docetaxel prolonged progression-free survival in patients with locally advanced or metastatic urothelial carcinoma.
Adding ramucirumab to docetaxel prolonged progression-free survival in patients with locally advanced or metastatic urothelial carcinoma.

Adding ramucirumab to docetaxel prolonged progression-free survival in patients with locally advanced or metastatic urothelial carcinoma in the second-line treatment setting, a study published in the Journal of Clinical Oncology has shown.1

For the phase 2 study, researchers sought to evaluate the efficacy and safety of docetaxel monotherapy or docetaxel in combination with the vascular endothelial growth factor receptor 2 (VEGFR2) antibody ramucirumab or the VEGFR1 antibody icrucumab following progression on or after platinum-based therapy in patients with locally advanced or metastatic urothelial carcinoma.

 

Researchers enrolled 140 patients and randomly assigned them 1:1:1 to receive 75 mg/m2 IV on day 1 of each 21-day cycle (arm A), docetaxel 75 mg/m2 IV plus ramucirumab 10 mg/kg IV on day 1 of each 21-day cycle (arm B), or docetaxel 75 mg/m2 IV on day 1 plus icrucumab 12 mg/kg IV on days 1 and 8 of each 21-day cycle (arm C). Treatment was continued until disease progression or unacceptable toxicity.

Results showed that median progression-free survival was 5.4 months (95% CI, 3.1 - 6.9) in arm B compared with 2.8 months (95% CI, 1.9 - 3.6) in arm A (HR, 0.389; 95% CI, 0.235 - 0.643; P = .0002), suggesting a significant benefit with ramucirumab.

In contrast, there was no significant difference in median progression-free survival in arm C compared with arm A (1.6 months; 95% CI, 1.4 - 2.9; HR, 0.863; 95% CI, 0.550 - 1.357; P = .5053).

In terms of safety, the most frequently observed grade 3 or worse adverse events were neutropenia (36%, 33%, and 39%), fatigue (13%, 30%, and 20%), febrile neutropenia (13%, 17%, and 6.1%), and anemia (6.7%, 13%, and 14%, respectively).

RELATED: Vinflunine Plus Gemcitabine May Be Safe, Effective for Urothelial Carcinoma

The findings suggested that the combination of docetaxel and ramucirumab for the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma warrants further investigation in a phase 3 trial.

The same combination is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based therapy.

Reference

  1. Petrylak DP, Tagawa ST, Kohli M, et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial [published online ahead of print February 29, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.65.0218.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters